| 0% | No more than topical therapy required over the past 12-month period and at least one of the following: Characteristic lesions involving less than 5 percent of the entire body affected; or Characteristic lesions involving less than 5 percent of exposed areas affected. | No more than topical therapy over the past 12-month period, and characteristic lesions cover less than 5 percent of your entire body or less than 5 percent of exposed areas. Over-the-counter and prescription antifungal creams are topical therapy. DC 7813 is evaluated under the General Rating Formula for the Skin, and that formula prints this 0 percent level directly: no monthly payment, but the condition is on record and a later increase runs from it. The lowest compensable level under this formula is 10 percent. |
|---|
What supports this level- Characteristic lesions measured at less than 5 percent of the entire body affected
- Less than 5 percent of exposed areas affected
- Topical antifungal treatment only over the past 12-month period, with no oral antifungals or other systemic therapy
- Dermatophytosis diagnosis confirmed, with KOH prep or fungal culture results if available
- A dated record of the condition so that a later increase claim has a starting point
|
| 10% | Evaluate under the General Rating Formula for the Skin. At least one of the following: Characteristic lesions involving at least 5 percent, but less than 20 percent, of the entire body affected; or At least 5 percent, but less than 20 percent, of exposed areas affected; or Intermittent systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of less than 6 weeks over the past 12-month period. | Characteristic lesions cover at least 5 percent but less than 20 percent of your entire body, or at least 5 percent but less than 20 percent of exposed areas, or you needed intermittent systemic therapy — oral antifungals count — for a total of less than 6 weeks over the past 12-month period. Any one of these on its own is enough. |
|---|
What supports this level- Body surface area measured at 5 percent to less than 20 percent of the entire body affected
- 5 percent to less than 20 percent of exposed areas affected
- Treatment records adding up to a total of less than 6 weeks of oral antifungal or other systemic therapy over the past 12-month period
- Prescription records for oral terbinafine, itraconazole, fluconazole, or griseofulvin with start and stop dates
- Dated photographs of the affected areas
|
| 30% | Evaluate under the General Rating Formula for the Skin. At least one of the following: Characteristic lesions involving 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected; or Systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of 6 weeks or more, but not constantly, over the past 12-month period. | Characteristic lesions cover 20 to 40 percent of your entire body or 20 to 40 percent of exposed areas, or you needed systemic therapy for a total of 6 weeks or more, but not constantly, over the past 12-month period. Either one on its own is enough. Note that 40 percent exactly falls in this band; the 60 percent level asks for MORE than 40 percent. |
|---|
What supports this level- Body surface area measured at 20 to 40 percent of the entire body or of exposed areas affected
- Treatment records adding up to a total of 6 weeks or more of oral antifungal or other systemic therapy over the past 12-month period, but not constant
- Prescription records for oral terbinafine, itraconazole, fluconazole, or griseofulvin with start and stop dates
- Dermatology or primary care notes documenting the course of therapy
- Documentation of each affected site — feet, groin, body, scalp, beard area, nails — so the total measured area is complete
|
| 60% | Evaluate under the General Rating Formula for the Skin. At least one of the following: Characteristic lesions involving more than 40 percent of the entire body or more than 40 percent of exposed areas affected; or Constant or near-constant systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, psoralen with long-wave ultraviolet-A light (PUVA), or other immunosuppressive drugs required over the past 12-month period. | Characteristic lesions cover more than 40 percent of your entire body or more than 40 percent of exposed areas, or you needed constant or near-constant systemic therapy over the past 12-month period. This is the highest level the General Rating Formula for the Skin provides. |
|---|
What supports this level- Body surface area measured at more than 40 percent of the entire body, or more than 40 percent of exposed areas affected
- Records showing constant or near-constant systemic therapy across the past 12-month period
- Continuous oral antifungal prescription history with no meaningful gap
- Treatment notes describing the therapy as ongoing rather than intermittent
|